RecallDepth
Class II Ongoing

Duloxetine Delayed-Release Capsules, USP, 60 mg, 90-count bottles, Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922, NDC: 51991-748-90.

This recall is currently active, issued May 15, 2024. It was issued by Breckenridge Pharmaceutical, Inc.

Company
Breckenridge Pharmaceutical, Inc
Recall Initiated
April 29, 2024
Posted
May 15, 2024
Recall Number
D-0484-2024
Voluntary / Mandated
Voluntary: Firm initiated
Quantity
281,554/90 count bottles
Firm Location
Berlin, CT, United States
Official Source
View on FDA website ↗

Reason for Recall

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

Distribution

US Nationwide.

Lot / Code Info

230028C: Exp. Nov 2025 230106C: Exp. Dec 2025 230170C: Exp. Dec 2025 220039: Exp. Dec 2024 220363: Exp. Feb 2025

More recalls by Breckenridge Pharmaceutical, Inc

View all recalls by this company →

Other recent Class II Drug recalls